Lumos FebriDx Sites Climb As Product Sales Surge, Despite Lower Quarterly Revenue
Lumos Diagnostics said FebriDx was being actively ordered and used at 265 US healthcare sites, up from 215 in mid-September and 170 in late July, while evaluations expanded to 485 sites from 405. Quarterly revenue fell 39% year on year to about US$2 million, but product revenue rose 224% and FebriDx sales increased 351%; the prior-year quarter included a one-off exclusivity fee. The company ended the quarter debt-free with approximately US$12 million in cash, while its paediatric study has enrolled fewer patients and bacterial-positive cases than planned.
Closing price · 2026-10-27: $0.064 · -23.81%